MPC1 Antibody

What is MPC1 and what role does it play in cellular metabolism?

MPC1 is a component of the mitochondrial pyruvate carrier complex that transports pyruvate across the mitochondrial membrane. It functions as a critical linker between glycolysis and intra-mitochondrial pyruvate metabolism, forming a complex with MPC2 to facilitate pyruvate transport. This transport mechanism is essential for cellular energy production and metabolic regulation, particularly in tissues with high mitochondrial content such as the liver . The MPC complex was molecularly identified and purified in 2012, revealing that it consists of two proteins: MPC1 (also known as BRP44L) and MPC2 (also known as BRP44) .

What are the optimal methods for MPC1 protein detection in tissue samples?

For detecting MPC1 protein in tissue samples, immunohistochemistry (IHC) staining and western blotting represent the two most reliable methods. When performing IHC, tissue sections should be properly fixed and processed before applying anti-MPC1 primary antibodies. The relative protein expression can be quantified using image analysis software such as Image-Pro Plus . For western blotting, fresh tissue samples should be properly lysed, and protein concentrations standardized before electrophoresis. Both techniques have been successfully employed to demonstrate that MPC1 protein expression is significantly downregulated in hepatocellular carcinoma compared to adjacent non-cancerous tissues .

How should researchers interpret discrepancies between MPC1 mRNA and protein expression?

Discrepancies between mRNA and protein expression levels are common with MPC1 and require careful interpretation. Research has shown that while MPC1 mRNA levels may be consistently decreased in tumor tissues, MPC2 mRNA levels can show variable patterns (upregulated in some samples and downregulated in others) . These discrepancies may be due to:

• Post-transcriptional regulation mechanisms

• Protein modifications such as phosphorylation, acetylation, or hydroxylation

• Changes in protein spatial position affecting detection

• Variations in protein turnover rates

When encountering such discrepancies, researchers should employ multiple detection methods and consider analyzing both transcript and protein levels to gain a complete understanding of MPC1 biology .

How is MPC1 expression altered across different cancer types and what are the implications?

MPC1 expression is consistently downregulated across multiple cancer types. In hepatocellular carcinoma, both MPC1 and MPC2 protein expression are significantly reduced compared to peritumoral tissues . In colorectal cancer (CRC), MPC1 shows a progressive decrease in expression from normal tissue to primary CRC to metastatic CRC .

Analysis of multiple GEO datasets (GSE21510, GSE5206, GSE20916, GSE9348, and GSE4183) consistently demonstrates MPC1 downregulation in CRC compared to normal tissues . This pattern suggests MPC1 downregulation may be a common feature in cancer progression and metastasis, potentially making it a valuable biomarker for cancer diagnosis and prognosis .

What is the relationship between MPC1 expression and cancer prognosis?

MPC1 expression shows significant correlation with cancer prognosis across multiple tumor types. Low MPC1 expression is associated with:

Multivariate regression analysis has indicated that MPC1 protein levels and microvascular invasion are positively associated with HCC recurrence (P=0.000 and P=0.017, respectively) . The prognostic value of MPC1 is particularly pronounced in patients with metastatic disease, suggesting its potential utility as a biomarker for identifying high-risk patients .

What methodological approaches can researchers use to study MPC1's role in cancer metastasis?

To investigate MPC1's role in cancer metastasis, researchers can employ several methodological approaches:

• Generate stable cell lines with MPC1 overexpression or knockdown using lentiviral transfection systems

• Utilize in vitro motility assays (migration and invasion) to assess metastatic potential

• Develop in vivo metastasis models, particularly liver metastasis models for colorectal cancer

• Examine downstream signaling pathways affected by MPC1 alteration, such as the Wnt/β-catenin pathway

• Analyze the expression of metastasis-related genes like MMP7, E-cadherin, Snail1, and myc in response to MPC1 modulation

For example, researchers have successfully demonstrated that MPC1 silencing enhances liver metastases in vivo, while MPC1 overexpression inhibits the motility of CRC cells in vitro .

What is the clinical significance of MPC1 expression in relation to tumor stage and metastasis?

MPC1 expression shows significant clinical correlations with tumor progression parameters. Analysis of MPC1 expression in relation to clinicopathological features reveals:

This data demonstrates that low MPC1 expression significantly correlates with metastasis (p=0.009), lymph node invasion (p=0.003), and advanced TNM stage (p=0.001) . These associations highlight MPC1's potential as a biomarker for identifying patients at higher risk for metastatic disease.

How can researchers effectively study MPC1 mutations and their functional impacts?

To study MPC1 mutations and their functional consequences, researchers can employ the following approaches:

• CRISPR/Cas9 gene editing to delete or modify MPC1 in cell lines (e.g., by targeting the 5'-UTR to beyond the translation start codon)

• Complementation experiments with wild-type or mutant MPC1 alleles in MPC1-knockout cells

• Pyruvate oxidation assays to assess functional impacts on mitochondrial pyruvate transport

• Western blotting to evaluate effects on MPC complex formation and stability

• Analysis of metabolic consequences using respirometry techniques

These approaches have been successfully used to investigate human patient MPC1 mutations (such as L79H, R97W, and A58G) and to demonstrate that C-terminal truncations (ΔC12 or ΔC18) of MPC1 fail to rescue pyruvate-driven respiration .

What techniques should researchers use to investigate MPC1's interaction with MPC2?

To investigate MPC1's interaction with MPC2 and the formation of the functional MPC complex, researchers can employ:

• Co-immunoprecipitation assays to detect physical interactions between MPC1 and MPC2

• Western blotting analysis to assess how MPC1 expression affects MPC2 stability (as MPC1 knockout often affects MPC2 protein levels)

• Blue native polyacrylamide gel electrophoresis to analyze intact MPC complexes

• Proximity ligation assays to visualize protein-protein interactions in situ

• Functional complementation studies in MPC1-deficient cells

Research has shown that MPC1 knockout can disrupt the MPC complex formation while preserving normal levels of MPC2 mRNA, indicating post-transcriptional regulation of the complex . Different MPC1 mutations can differentially affect MPC2 protein levels, providing insights into the structural requirements for complex formation .

How does MPC1 expression correlate with immune cell infiltration in tumors?

MPC1 expression shows significant correlations with immune cell infiltration across multiple cancer types. Analysis using TIMER2.0 demonstrates that MPC1 expression is associated with immune purity and immune cell infiltration in 26 different cancer types .

In thymoma (THYM), MPC1 expression shows strong positive correlations with infiltrating:

• B cells (r = 0.647, P = 7.57e-15)

• CD8+ T cells (r = 0.54, P = 5.59e-10)

• CD4+ T cells (r = 0.569, P = 7.57e-11)

• Macrophages (r = 0.529, P = 1.50e-09)

• Dendritic cells (r = 0.661, P = 1.16e-15)

Conversely, some cancer types show negative correlations between MPC1 expression and immune cell infiltration. These findings suggest that MPC1 may influence the tumor immune microenvironment, potentially through metabolic reprogramming effects .

What are the optimal immunohistochemistry protocols for MPC1 detection in tissue samples?

For optimal MPC1 detection in tissue samples using immunohistochemistry:

• Use formalin-fixed, paraffin-embedded tissue sections (4-5μm thick)

• Perform antigen retrieval using citrate buffer (pH 6.0) at high temperature

• Block endogenous peroxidase activity with hydrogen peroxide

• Apply appropriate blocking solution to reduce non-specific binding

• Incubate with validated anti-MPC1 primary antibody (optimal dilution should be determined empirically)

• Use a detection system compatible with your primary antibody (e.g., HRP-conjugated secondary antibody)

• Develop with DAB or other chromogen and counterstain with hematoxylin

• Quantify staining using image analysis software like Image-Pro Plus

The scoring of MPC1 expression can be based on staining area and intensity, commonly categorized as "-, +, ++, +++" for semi-quantitative analysis .

How should researchers design experiments to study the metabolic consequences of MPC1 modulation?

To study metabolic consequences of MPC1 modulation, researchers should consider:

• Generating stable cell lines with MPC1 overexpression, knockdown, or knockout using appropriate vectors and selection markers

• Measuring cellular respiration using techniques such as Seahorse XF analysis to quantify:

  • Basal respiration

  • ATP production

  • Maximal respiratory capacity

  • Spare respiratory capacity

  • Pyruvate-driven respiration specifically

• Assessing glycolytic parameters (extracellular acidification rate)

• Analyzing metabolite profiles using mass spectrometry to identify altered metabolic pathways

• Measuring mitochondrial pyruvate uptake using radiolabeled pyruvate

• Evaluating the expression of key metabolic enzymes affected by pyruvate metabolism alterations

When studying pyruvate-driven respiration specifically, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) can be used to stimulate and measure maximal respiratory capacity .

What experimental models are most appropriate for studying MPC1 in cancer research?

Researchers investigating MPC1 in cancer should consider multiple experimental models:

• Cell line models:

  • Human cancer cell lines (e.g., Lovo, SW480 for CRC studies)

  • Mouse cell lines (e.g., MC38-Luc for in vivo tracking)

  • CRISPR/Cas9-modified lines with MPC1 knockout or knockdown

• Animal models:

  • Chemically induced cancer models (e.g., AOM/DSS-induced CRC model)

  • Xenograft models using MPC1-modified cell lines

  • Metastasis models (e.g., liver metastasis models for CRC)

• Patient-derived samples:

  • Primary tumor tissues

  • Adjacent non-tumor tissues

  • Metastatic lesions

  • Tissue microarrays for high-throughput analysis

Each model offers specific advantages depending on the research question, with cell lines providing mechanistic insights, animal models offering in vivo relevance, and patient samples ensuring clinical significance.

How can researchers address variability in MPC1 antibody performance across different applications?

To address variability in MPC1 antibody performance:

• Validate antibody specificity using positive and negative controls (e.g., MPC1 knockout cells)

• Determine optimal working concentrations and conditions for each application (IHC, western blot, immunofluorescence)

• Consider using multiple antibodies targeting different epitopes of MPC1

• Include appropriate loading controls and normalization procedures

• Account for potential differences in antibody affinities for different species (human vs. mouse) when designing cross-species studies

• Perform parallel complementation experiments in both human and mouse cell lines to confirm findings

Research has shown that antibody affinity can differ between mouse, human, and mutated human MPC proteins, potentially affecting experimental results and interpretation .

What strategies can help resolve discrepancies between functional and expression studies of MPC1?

To resolve discrepancies between MPC1 functional and expression studies:

• Employ multiple techniques to measure MPC1 expression (qPCR, western blot, IHC)

• Use functional assays (pyruvate oxidation) alongside expression analysis

• Consider post-translational modifications that might affect protein function without altering expression

• Investigate the integrity of the MPC complex rather than individual components alone

• Examine regulatory mechanisms that might explain discordant mRNA and protein levels

• Consider cell type-specific and context-dependent effects on MPC1 function and expression

• Verify the specificity of observed phenotypes using rescue experiments

Research has demonstrated that while MPC1 mRNA levels may be consistently decreased in tumors, MPC2 mRNA levels can show variable patterns, highlighting the importance of comprehensive analysis .

How can researchers effectively investigate the relationship between MPC1 and specific signaling pathways in cancer?

To investigate MPC1's relationship with signaling pathways in cancer:

• Perform pathway analysis following MPC1 modulation (overexpression or knockdown)

• Use reporter assays to measure the activity of specific signaling pathways (e.g., Wnt/β-catenin pathway)

• Analyze the subcellular localization of key pathway components (e.g., β-catenin nuclear translocation)

• Measure the expression of pathway target genes at mRNA and protein levels

• Use pathway inhibitors to determine whether observed phenotypes are pathway-dependent

• Perform co-immunoprecipitation experiments to identify potential physical interactions between MPC1 and pathway components

• Validate findings using multiple cell lines and in vivo models

Research has shown that decreased MPC1 can activate the Wnt/β-catenin pathway by promoting nuclear translocation of β-catenin, subsequently affecting the expression of target genes like MMP7, E-cadherin, Snail1, and myc .